Theriva Biologics, Inc. Recovery of Direct Costs
Theriva Biologics, Inc. (TOVX) reported Recovery of Direct Costs of $0 for the 3-month period ending 2012-03-31, per its 10-Q filed 2012-05-15.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RecoveryOfDirectCosts · last filed 2012-05-15
- Theriva Biologics, Inc. recovery of direct costs for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
- Theriva Biologics, Inc. recovery of direct costs for the quarter ending 2011-03-31 was $296.00K.
- Theriva Biologics, Inc. recovery of direct costs for fiscal 2011 was $539.00K, a 368.70% increase from fiscal 2010.
- Theriva Biologics, Inc. recovery of direct costs for fiscal 2010 was $115.00K.
| Period end | Recovery of Direct Costs 3 month | Recovery of Direct Costs 12 month |
|---|---|---|
| 2012-03-31 | $0.00 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $539.00K 10-K/A · filed 2012-05-11 | |
| 2011-03-31 | $296.00K 10-Q · filed 2012-05-15 | |
| 2010-12-31 | $115.00K 10-K/A · filed 2012-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| KALA BIO, Inc. (KALA) | United States | $0.011B | -3.33 |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |